The New England journal of medicine, 2023-09, Vol.389 (10), p.911-921
- Chen, Alice P.
- Sharon, Elad
- O’Sullivan-Coyne, Geraldine
- Moore, Nancy
- Foster, Jared C.
- Hu, James S.
- Van Tine, Brian A.
- Conley, Anthony P.
- Read, William L.
- Riedel, Richard F.
- Burgess, Melissa A.
- Glod, John
- Davis, Elizabeth J.
- Merriam, Priscilla
- Naqash, Abdul R.
- Fino, Kristin K.
- Miller, Brandon L.
- Wilsker, Deborah F.
- Begum, Asma
- Ferry-Galow, Katherine V.
- Deshpande, Hari A.
- Schwartz, Gary K.
- Ladle, Brian H.
- Okuno, Scott H.
- Beck, Jill C.
- Chen, James L.
- Takebe, Naoko
- Fogli, Laura K.
- Rosenberger, Christina L.
- Parchment, Ralph E.
- Doroshow, James H.
2023
Details
- Autor(en) / Beteiligte
- Chen, Alice P.
- Sharon, Elad
- O’Sullivan-Coyne, Geraldine
- Moore, Nancy
- Foster, Jared C.
- Hu, James S.
- Van Tine, Brian A.
- Conley, Anthony P.
- Read, William L.
- Riedel, Richard F.
- Burgess, Melissa A.
- Glod, John
- Davis, Elizabeth J.
- Merriam, Priscilla
- Naqash, Abdul R.
- Fino, Kristin K.
- Miller, Brandon L.
- Wilsker, Deborah F.
- Begum, Asma
- Ferry-Galow, Katherine V.
- Deshpande, Hari A.
- Schwartz, Gary K.
- Ladle, Brian H.
- Okuno, Scott H.
- Beck, Jill C.
- Chen, James L.
- Takebe, Naoko
- Fogli, Laura K.
- Rosenberger, Christina L.
- Parchment, Ralph E.
- Doroshow, James H.
- Titel
- Atezolizumab for Advanced Alveolar Soft Part Sarcoma
- Ist Teil von
- The New England journal of medicine, 2023-09, Vol.389 (10), p.911-921
- Ort / Verlag
- United States: Massachusetts Medical Society
- Erscheinungsjahr
- 2023
- Link zum Volltext
- Quelle
- MEDLINE
- Beschreibungen/Notizen
- Alveolar soft part sarcoma is a rare mesenchymal tumor with characteristic gene rearrangement that creates an ASPL–TFE3 fusion protein. In a phase 2 study, atezolizumab induced responses in 37% of the patients.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0028-4793eISSN: 1533-4406DOI: 10.1056/NEJMoa2303383Titel-ID: cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10729808
- Format
- –
- Schlagworte
- Administration, Intravenous, Adolescent, Adult, Age, Alveoli, Antibodies, Monoclonal, Humanized - administration & dosage, Antibodies, Monoclonal, Humanized - adverse effects, Antibodies, Monoclonal, Humanized - therapeutic use, B7-H1 Antigen - antagonists & inhibitors, Biopsy, Body Weight, Cancer, Child, Childhood Diseases, Cloning, Drug dosages, Enrollments, FDA approval, Genetics, Hematology, Humans, Hypotheses, Immune checkpoint inhibitors, Immunotherapy, Infant, Newborn, Kinases, Medical prognosis, Metastasis, Monoclonal antibodies, Oncology, Oncology General, Patients, PD-L1 protein, Pediatrics, Pediatrics General, Pharmacodynamics, R&D, Research & development, Sarcoma, Sarcoma, Alveolar Soft Part - drug therapy, Solid tumors, Survival, Targeted cancer therapy, Tomography, Treatments in Oncology, Tumors